Analysts See $-0.09 EPS for Senomyx, Inc. (SNMX); 8 Bullish Analysts Covering Endo International plc (ENDP)

April 9, 2018 - By Nellie Frank

Analysts expect Senomyx, Inc. (NASDAQ:SNMX) to report $-0.09 EPS on April, 26.They anticipate $0.02 EPS change or 28.57% from last quarter’s $-0.07 EPS. After having $0.15 EPS previously, Senomyx, Inc.’s analysts see -160.00% EPS growth. The stock increased 2.97% or $0.03 during the last trading session, reaching $1.04. About 56,177 shares traded. Senomyx, Inc. (NASDAQ:SNMX) has declined 7.31% since April 9, 2017 and is downtrending. It has underperformed by 18.86% the S&P500.

Among 25 analysts covering Endo International plc (NASDAQ:ENDP), 8 have Buy rating, 1 Sell and 16 Hold. Therefore 32% are positive. Endo International plc had 91 analyst reports since August 11, 2015 according to SRatingsIntel. Mizuho upgraded Endo International plc (NASDAQ:ENDP) on Friday, August 12 to “Buy” rating. Deutsche Bank maintained it with “Buy” rating and $68 target in Friday, March 18 report. The rating was maintained by Barclays Capital with “Equal Weight” on Friday, May 6. The firm has “Hold” rating given on Friday, September 15 by Stifel Nicolaus. The firm has “Equal-Weight” rating given on Thursday, January 21 by Barclays Capital. The firm has “Buy” rating by Mizuho given on Friday, January 19. The firm earned “Neutral” rating on Monday, June 13 by Mizuho. The stock of Endo International plc (NASDAQ:ENDP) earned “Buy” rating by FBR Capital on Tuesday, February 13. Nomura initiated the stock with “Buy” rating in Tuesday, September 29 report. The rating was initiated by Guggenheim with “Hold” on Friday, June 16. See Endo International plc (NASDAQ:ENDP) latest ratings:

05/03/2018 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Market Perform Old Target: $10 New Target: $9 Maintain
28/02/2018 Broker: William Blair Rating: Hold Maintain
28/02/2018 Broker: Gabelli Old Rating: Buy New Rating: Hold Downgrade
26/02/2018 Broker: JMP Securities Old Rating: Outperform New Rating: Market Perform Downgrade
23/02/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $15 New Target: $10 Maintain
21/02/2018 Broker: Canaccord Genuity Old Rating: Hold New Rating: Hold Old Target: $8 New Target: $7 Maintain
13/02/2018 Broker: FBR Capital Rating: Buy New Target: $10.0 Initiate
19/01/2018 Broker: Mizuho Rating: Buy New Target: $12.0 Maintain
03/01/2018 Broker: Mizuho Rating: Buy New Target: $12.0 Maintain
02/01/2018 Broker: Stifel Nicolaus Rating: Hold New Target: $10.0 Maintain

Investors sentiment increased to 1.13 in Q4 2017. Its up 0.01, from 1.12 in 2017Q3. It improved, as 37 investors sold Endo International plc shares while 61 reduced holdings. 39 funds opened positions while 72 raised stakes. 203.77 million shares or 0.47% more from 202.81 million shares in 2017Q3 were reported. Bogle Invest Mngmt Limited Partnership De holds 1.12% or 1.97 million shares in its portfolio. Northern Trust Corp has 0% invested in Endo International plc (NASDAQ:ENDP) for 1.82 million shares. 30,620 were accumulated by Jensen Inv. Ubs Asset Management Americas Incorporated reported 221,992 shares or 0% of all its holdings. Nuwave Invest Mngmt Ltd Liability Corporation owns 132 shares. Point72 Asia (Hong Kong) Limited invested in 2,200 shares. Assetmark reported 274 shares or 0% of all its holdings. Cubist Systematic Strategies Ltd Co invested in 92,877 shares or 0.04% of the stock. Raymond James Financial Svcs Advisors invested in 0% or 25,190 shares. Quantbot Technologies Limited Partnership accumulated 25,894 shares. 50,000 were reported by Hudson Bay Capital Mngmt Limited Partnership. Tctc Hldg Ltd Liability Corp invested 0.02% of its portfolio in Endo International plc (NASDAQ:ENDP). River & Mercantile Asset Llp reported 475,650 shares. Chicago Equity Ptnrs Llc accumulated 0.1% or 421,475 shares. Highbridge Cap Management Ltd Liability Com, New York-based fund reported 24,967 shares.

Endo International plc develops, manufactures, and distributes pharmaceutical products and devices worldwide. The company has market cap of $1.23 billion. The Company’s U.S. It currently has negative earnings. Generic Pharmaceuticals segment provides tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics, and transdermal patches for pain management, urology, central nervous system disorders, immunosuppression, oncology, womenÂ’s health, and cardiovascular disease markets.

The stock decreased 4.02% or $0.23 during the last trading session, reaching $5.49. About 4.21M shares traded. Endo International plc (NASDAQ:ENDP) has declined 44.86% since April 9, 2017 and is downtrending. It has underperformed by 56.41% the S&P500.